Developing Products to Sustain Life

Hemorrhagic shock due to severe blood loss causes more than 80,000 deaths annually in the U.S. Additionally, there are over 500,000 emergency room admissions related to trauma annually in the U.S., and when hemorrhagic shock occurs, these patients stay in the ICU for 2.7 days at an average cost of more than $17,000. This clinically tragic and economically significant dilemma continues today because there are currently no good therapies for first responder treatment of hemorrhagic shock.

VitalMedix, Inc. is a development stage company that has obtained an exclusive global license from the University of Minnesota for a proprietary new formulation called Tamiasyn™. VitalMedix will incorporate Tamiasyn into a combination drug/delivery device product named O2 Rescue™ that will be used by first responders and medics to treat this condition.